IL44618A - Pharmaceutical compositions comprising mixed salts of polysulfuric esters of naturally occurring glycopeptides with metals and organic bases - Google Patents
Pharmaceutical compositions comprising mixed salts of polysulfuric esters of naturally occurring glycopeptides with metals and organic basesInfo
- Publication number
- IL44618A IL44618A IL44618A IL4461874A IL44618A IL 44618 A IL44618 A IL 44618A IL 44618 A IL44618 A IL 44618A IL 4461874 A IL4461874 A IL 4461874A IL 44618 A IL44618 A IL 44618A
- Authority
- IL
- Israel
- Prior art keywords
- base
- composition according
- salts
- anisotropine
- mixed
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title claims abstract description 40
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 8
- 229910052751 metal Inorganic materials 0.000 title claims description 10
- 239000002184 metal Substances 0.000 title claims description 10
- 150000007530 organic bases Chemical class 0.000 title claims description 7
- 108010015899 Glycopeptides Proteins 0.000 title description 6
- 102000002068 Glycopeptides Human genes 0.000 title description 6
- 150000002739 metals Chemical class 0.000 title description 4
- 150000002148 esters Chemical class 0.000 title description 3
- 239000002585 base Substances 0.000 claims abstract description 16
- 238000011282 treatment Methods 0.000 claims abstract description 13
- 239000003513 alkali Substances 0.000 claims abstract description 4
- 239000000812 cholinergic antagonist Substances 0.000 claims abstract description 4
- 230000002048 spasmolytic effect Effects 0.000 claims abstract description 4
- 125000000129 anionic group Chemical group 0.000 claims abstract 2
- 229920000447 polyanionic polymer Polymers 0.000 claims abstract 2
- 239000000203 mixture Substances 0.000 claims description 18
- 150000001768 cations Chemical class 0.000 claims description 3
- 238000000576 coating method Methods 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000013543 active substance Substances 0.000 claims 1
- 239000011248 coating agent Substances 0.000 claims 1
- 230000002183 duodenal effect Effects 0.000 claims 1
- 150000002892 organic cations Chemical class 0.000 claims 1
- 108010024093 sulglicotide Proteins 0.000 abstract description 11
- 229910052784 alkaline earth metal Inorganic materials 0.000 abstract description 5
- 208000015877 Duodenal disease Diseases 0.000 abstract description 4
- -1 alkaline-earth metal cation Chemical class 0.000 abstract description 3
- 230000001078 anti-cholinergic effect Effects 0.000 abstract description 2
- 125000002091 cationic group Chemical group 0.000 abstract 1
- XGGHHHBGPSNXFE-ZSHCYNCHSA-N chembl1186610 Chemical compound C1[C@H](OC(=O)C(CCC)CCC)C[C@@H]2CC[C@H]1[N+]2(C)C XGGHHHBGPSNXFE-ZSHCYNCHSA-N 0.000 description 17
- 229940118324 anisotropine Drugs 0.000 description 13
- 239000011734 sodium Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 7
- 230000028327 secretion Effects 0.000 description 7
- 241000700159 Rattus Species 0.000 description 6
- 230000002467 anti-pepsin effect Effects 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 230000000144 pharmacologic effect Effects 0.000 description 6
- 229910052708 sodium Inorganic materials 0.000 description 5
- 208000025865 Ulcer Diseases 0.000 description 4
- 230000001262 anti-secretory effect Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 229950005306 octatropine methylbromide Drugs 0.000 description 4
- 159000000000 sodium salts Chemical class 0.000 description 4
- 231100000397 ulcer Toxicity 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 210000001187 pylorus Anatomy 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 208000007107 Stomach Ulcer Diseases 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000004051 gastric juice Anatomy 0.000 description 2
- 229910001385 heavy metal Inorganic materials 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 description 2
- 229960001549 ropivacaine Drugs 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 229930008281 A03AD01 - Papaverine Natural products 0.000 description 1
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 206010052402 Gastrointestinal hypermotility Diseases 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- NEYNJQRKHLUJRU-DZUOILHNSA-N Pentagastrin Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CCNC(=O)OC(C)(C)C)CCSC)C(N)=O)C1=CC=CC=C1 NEYNJQRKHLUJRU-DZUOILHNSA-N 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical class N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- XGGHHHBGPSNXFE-XYPWUTKMSA-N [(1r,5s)-8,8-dimethyl-8-azoniabicyclo[3.2.1]octan-3-yl] 2-propylpentanoate Chemical class C1C(OC(=O)C(CCC)CCC)C[C@@H]2CC[C@H]1[N+]2(C)C XGGHHHBGPSNXFE-XYPWUTKMSA-N 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 210000001564 haversian system Anatomy 0.000 description 1
- 208000008384 ileus Diseases 0.000 description 1
- 208000018936 intestinal hypermotility Diseases 0.000 description 1
- 230000037036 intestinal hypermotility Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- APVPOHHVBBYQAV-UHFFFAOYSA-N n-(4-aminophenyl)sulfonyloctadecanamide Chemical class CCCCCCCCCCCCCCCCCC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 APVPOHHVBBYQAV-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229960001789 papaverine Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/18—Aralkyl radicals
- C07D217/20—Aralkyl radicals with oxygen atoms directly attached to the aromatic ring of said aralkyl radical, e.g. papaverine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
- C07D451/06—Oxygen atoms
- C07D451/10—Oxygen atoms acylated by aliphatic or araliphatic carboxylic acids, e.g. atropine, scopolamine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F1/00—Compounds containing elements of Groups 1 or 11 of the Periodic Table
- C07F1/005—Compounds containing elements of Groups 1 or 11 of the Periodic Table without C-Metal linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/30—Extraction; Separation; Purification by precipitation
- C07K1/32—Extraction; Separation; Purification by precipitation as complexes
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT22212/73A IT1061352B (it) | 1973-03-27 | 1973-03-27 | Sali misti di esteri polisolforici di glicopeptidi naturali con metalli e con basi organiche e procedimento per la loro preparazione |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL44618A0 IL44618A0 (en) | 1974-07-31 |
| IL44618A true IL44618A (en) | 1977-03-31 |
Family
ID=11193113
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL44618A IL44618A (en) | 1973-03-27 | 1974-04-12 | Pharmaceutical compositions comprising mixed salts of polysulfuric esters of naturally occurring glycopeptides with metals and organic bases |
| IL44619A IL44619A (en) | 1973-03-27 | 1974-04-12 | Mixed salts of polysulfuric esters of naturally occurring glycopeptides with metals and organic bases and process for producing same |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL44619A IL44619A (en) | 1973-03-27 | 1974-04-12 | Mixed salts of polysulfuric esters of naturally occurring glycopeptides with metals and organic bases and process for producing same |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US3926921A (it) |
| JP (1) | JPS5029727A (it) |
| AR (1) | AR204623A1 (it) |
| AT (1) | AT347608B (it) |
| AU (1) | AU476679B2 (it) |
| BE (2) | BE812904A (it) |
| CA (1) | CA1023352A (it) |
| CH (1) | CH591244A5 (it) |
| DE (2) | DE2413803A1 (it) |
| ES (1) | ES424636A1 (it) |
| FR (2) | FR2223012B1 (it) |
| GB (1) | GB1410296A (it) |
| IE (1) | IE39191B1 (it) |
| IL (2) | IL44618A (it) |
| IT (1) | IT1061352B (it) |
| NL (1) | NL7404167A (it) |
| NO (1) | NO145272C (it) |
| PH (1) | PH11790A (it) |
| PL (1) | PL92521B1 (it) |
| RO (1) | RO65567A (it) |
| SE (1) | SE416131B (it) |
| YU (1) | YU83574A (it) |
| ZA (2) | ZA741976B (it) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1190133B (it) * | 1986-06-19 | 1988-02-10 | Chiesi Farma Spa | Derivati di acido valproico e di acido (e)-2-valproenoico,procedimento per la loro preparazione e relative composizioni farmaceutiche |
| JPS63162561A (ja) * | 1986-12-25 | 1988-07-06 | 株式会社吉兆総合商事 | 無塩素防水剤含有セメント組成物 |
| IT1215332B (it) * | 1987-01-12 | 1990-02-08 | Crinos Industria Farmaco | Composizione farmaceutica contenente sulglicotide per la terapia dell'ulcera gastrica |
| KR101819709B1 (ko) * | 2017-01-13 | 2018-01-17 | (주)아이엠디팜 | 설글리코타이드 또는 이의 약학적으로 허용가능한 염을 포함하는 안구건조증의 예방 또는 치료용 약학 조성물 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3174899A (en) * | 1960-12-30 | 1965-03-23 | Ciba Geigy Corp | Composition for the management of post antibiotic enteritis |
| BE633486A (it) * | 1962-06-18 | |||
| US3441646A (en) * | 1965-01-22 | 1969-04-29 | Commercial Solvents Corp | Bacitracin metal methane sulfinate and process for producing |
| IT1056709B (it) * | 1967-02-23 | 1982-02-20 | Prino G | Derivati solfonati d un glicopepti de esteratto da organi animali utili come farmaci e processo per la loro preparazione |
| US3476738A (en) * | 1967-12-04 | 1969-11-04 | Upjohn Co | Pentakis(n-(sulfomethyl))circulin and salts thereof |
| US3607650A (en) * | 1970-05-15 | 1971-09-21 | Prephar | Process for the enzymatic extraction and purification of a glycopeptide obtained from animal organs,useful as a drug |
-
1973
- 1973-03-27 IT IT22212/73A patent/IT1061352B/it active
-
1974
- 1974-01-01 AR AR252983A patent/AR204623A1/es active
- 1974-03-13 AT AT208174A patent/AT347608B/de not_active IP Right Cessation
- 1974-03-22 US US453764A patent/US3926921A/en not_active Expired - Lifetime
- 1974-03-22 US US453765A patent/US3900458A/en not_active Expired - Lifetime
- 1974-03-22 DE DE2413803A patent/DE2413803A1/de not_active Withdrawn
- 1974-03-22 FR FR7409914A patent/FR2223012B1/fr not_active Expired
- 1974-03-22 DE DE2413802A patent/DE2413802C2/de not_active Expired
- 1974-03-25 FR FR7410131A patent/FR2223015B1/fr not_active Expired
- 1974-03-25 CH CH414674A patent/CH591244A5/xx not_active IP Right Cessation
- 1974-03-25 SE SE7404014A patent/SE416131B/xx unknown
- 1974-03-26 PH PH15659A patent/PH11790A/en unknown
- 1974-03-26 CA CA195,978A patent/CA1023352A/en not_active Expired
- 1974-03-26 ES ES424636A patent/ES424636A1/es not_active Expired
- 1974-03-26 RO RO7478188A patent/RO65567A/ro unknown
- 1974-03-26 NO NO741079A patent/NO145272C/no unknown
- 1974-03-26 YU YU00835/74A patent/YU83574A/xx unknown
- 1974-03-26 AU AU67165/74A patent/AU476679B2/en not_active Expired
- 1974-03-27 PL PL1974169863A patent/PL92521B1/pl unknown
- 1974-03-27 JP JP49033595A patent/JPS5029727A/ja active Pending
- 1974-03-27 IE IE672/74A patent/IE39191B1/xx unknown
- 1974-03-27 BE BE142510A patent/BE812904A/xx not_active IP Right Cessation
- 1974-03-27 NL NL7404167A patent/NL7404167A/xx unknown
- 1974-03-27 ZA ZA00741976A patent/ZA741976B/xx unknown
- 1974-03-27 BE BE142509A patent/BE812903A/xx not_active IP Right Cessation
- 1974-03-27 ZA ZA00741977A patent/ZA741977B/xx unknown
- 1974-03-27 GB GB1361174A patent/GB1410296A/en not_active Expired
- 1974-04-12 IL IL44618A patent/IL44618A/en unknown
- 1974-04-12 IL IL44619A patent/IL44619A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69114117T2 (de) | Neue Verwendung von Peptidderivat. | |
| DE69839046T2 (de) | VERWENDUNG VON einem Faktor a inhibierenden Oligosacchariden MIT EINEM BLUTGERINNUNGSHEMMENDEN MITTEL ZUR BEHANDLUNG VON ARTERIENTHROMBOSEN | |
| WO1992001675A3 (en) | Substituted bicyclic bis-aryl compounds exhibiting selective leukotriene b4 antagonist activity, their preparation and use in pharmaceutical compositions | |
| EP0178124B1 (en) | Improved antiinflammatory salts of piroxicam | |
| EP0551927B1 (de) | Verfahren zur Behandlung der Herzinsuffizienz | |
| IL44618A (en) | Pharmaceutical compositions comprising mixed salts of polysulfuric esters of naturally occurring glycopeptides with metals and organic bases | |
| DE60127535T2 (de) | Vorbeugende oder therapeutische mittel gegen gastrische oder ösophageale regurgitation | |
| Reuber et al. | Edetate kidney lesions in rats | |
| DE2739440A1 (de) | Pentapeptide und sie enthaltende arzneimittel | |
| DE3786187T2 (de) | Chemische Verbindung. | |
| DE10356409B4 (de) | Neues Arzneimittel Oxachelin und Derivate | |
| JPS63225317A (ja) | 抗消化性潰瘍剤 | |
| EP0056973B1 (en) | Pharmaceutical compositions | |
| WO1993007864A1 (en) | Use of suramine and related compounds as contraceptive agents | |
| US3995055A (en) | Method for treating peptic ulcers | |
| GB1577868A (en) | Agent for protecting against renal failure | |
| EP0049853B1 (de) | Neue Prostaglandine, ihre Herstellung und pharmazeutische Kompositionen | |
| CA1060344A (en) | Antihypertonic agent | |
| CH667994A5 (de) | Pharmazeutische zusammensetzungen mit polypeptid-wirkstoffen. | |
| US3629445A (en) | Method of preventing excessive secretion of hydrochloric acid | |
| EP0597415B1 (en) | Iron therapy using Saccharose octasulfate ferric complex | |
| DE2550992C2 (it) | ||
| US4470974A (en) | Gastric cytoprotection with L-363,586 | |
| US3670088A (en) | Method of treating hyperchlorhydria and/or associated conditions | |
| US4036981A (en) | Method for treating inflammation |